VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
PODDInsulet Corporation
$158.25$11.1B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksPODDFinancials

Insulet Corporation (PODD) Financials

22Y historyFree accessUpdated daily

Revenue growth has accelerated to 33.9% as of 2026Q1, though operating margins remain inconsistent, fluctuating between 11.2% and 20.9% over the last ten quarters due to elevated SG&A spending.

PODD Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04
Sales/Revenue2.9B2.71B2.07B1.7B1.31B1.1B904.4M738.2M563.82M463.77M366.99M263.89M288.72M247.08M211.37M152.25M96.97M66.03M36.06M13.37M3.66M50K0
Revenue Growth %31.93%30.73%22.07%30.02%18.79%21.49%22.51%30.93%21.57%26.37%39.07%-8.6%16.85%16.9%38.83%57.02%46.85%83.12%169.66%265.06%7226%--
Cost of Goods Sold840.9M768.2M625.9M537.2M499.7M346.7M322.1M257.9M193.66M186.6M155.9M130.62M145.43M134.68M119.03M85.54M53.24M47.73M40.64M25.73M15.66M1.53M0
COGS % of Revenue-28.37%30.21%31.65%38.28%31.55%35.61%34.94%34.35%40.24%42.48%49.5%50.37%54.51%56.32%56.18%54.91%72.29%112.71%192.44%427.52%3060%-
Gross Profit2.06B1.94B1.45B1.16B805.6M752.1M582.3M480.3M370.17M277.17M211.09M133.27M143.29M112.4M92.34M66.71M43.73M18.3M-4.58M-12.36M-12M-1.48M0
Gross Margin %71.01%71.63%69.79%68.35%61.72%68.45%64.39%65.06%65.65%59.76%57.52%50.5%49.63%45.49%43.68%43.82%45.09%27.71%-12.71%-92.44%-327.52%-2960%-
Gross Profit Growth %-34.18%24.64%43.98%7.11%29.16%21.24%29.75%33.55%31.31%58.39%-6.99%27.48%21.73%38.41%52.57%138.98%499.15%62.92%-3.03%-710.61%--
Operating Expenses1.55B1.47B1.14B939.9M768M626.1M530.8M430.3M342.8M284.6M221.79M182.01M136M141.54M128.31M109.18M82.36M77.66M84.76M41.48M22.65M20.02M14.15M
OpEx % of Revenue-54.14%54.88%55.38%58.84%56.98%58.69%58.29%60.8%61.37%60.44%68.97%47.1%57.28%60.7%71.71%84.94%117.6%235.05%310.21%618.29%40050%-
Selling, General & Admin1.22B1.17B917.2M734.9M587.8M466M384M298M248M208.9M166.08M138.8M108.1M119.77M103.95M87.32M61.36M64.42M63.48M30.06M14.55M9.26M5.13M
SG&A % of Revenue-43.02%44.27%43.3%45.03%42.41%42.46%40.37%43.99%45.04%45.25%52.6%37.44%48.47%49.18%57.35%63.28%97.57%176.06%224.82%397.32%18522%-
Research & Development331.2M301.1M219.6M205M180.2M160.1M146.8M132.3M88.61M74.45M55.71M43.21M27.9M21.77M24.36M21.86M16.57M13.23M13.1M10.39M8.09M10.76M9.03M
R&D % of Revenue-11.12%10.6%12.08%13.81%14.57%16.23%17.92%15.72%16.05%15.18%16.37%9.66%8.81%11.52%14.36%17.08%20.04%36.34%77.71%220.97%21528%-
Other Operating Expenses00000000000000004.43M08.17M1.03M000
Operating Income507.2M473.8M308.9M220M37.6M126M51.5M50M27.4M-7.4M-10.7M-48.74M-8.87M-29.14M-35.97M-42.47M-38.63M-59.36M-89.34M-53.84M-34.65M-21.5M-14.15M
Operating Margin %17.48%17.5%14.91%12.96%2.88%11.47%5.69%6.77%4.86%-1.6%-2.92%-18.47%-3.07%-11.79%-17.02%-27.89%-39.84%-89.89%-247.77%-402.65%-945.81%-43010%-
Operating Income Growth %-53.38%40.41%485.11%-70.16%144.66%3%82.48%470.27%30.87%78.04%-449.2%69.54%19%15.3%-9.92%34.92%33.56%-65.93%-55.41%-61.1%-51.95%-
EBITDA582.1M586.9M389.7M292.8M100.8M183.4M106.9M77.9M43M6.5M3.13M-32.9M3.35M-17.33M-24.94M-33.96M-33.56M-54.14M-82.97M-48.92M-32.01M-20.27M-13.83M
EBITDA Margin %20.07%21.67%18.81%17.25%7.72%16.69%11.82%10.55%7.63%1.4%0.85%-12.47%1.16%-7.01%-11.8%-22.31%-34.61%-81.99%-230.09%-365.85%-873.74%-40538%-
EBITDA Growth %37.16%50.6%33.09%190.48%-45.04%71.56%37.23%81.16%561.54%107.73%109.51%-1082.32%119.33%30.52%26.57%-1.22%38.02%34.75%-69.59%-52.86%-57.9%-46.56%-
D&A (Non-Cash Add-back)74.9M113.1M80.8M72.8M63.2M57.4M55.4M27.9M15.6M13.9M13.83M15.84M12.22M11.81M11.03M8.5M5.08M5.22M6.38M4.92M2.64M1.24M323K
EBIT454.8M473.8M342.9M250.8M45.8M82.2M54.9M46.3M31.5M-7.5M-12.43M-48.68M-33.3M-27.98M-35.86M-42.33M-38.47M-59.12M-81.17M-53.84M-34.65M-21.5M-13.82M
Net Interest Income-20.6M-45M-3.2M-7.6M-26.7M-61.2M-45.1M-34.6M-21.3M-18.6M-13.56M-12.65M-14.58M-16.77M-15.68M-14.58M-22.53M-12.98M-5.43M0000
Interest Income24.4M34.7M39.5M28.6M9.3M500K3M06.71M2.63M825K58K129K124K110K139K168K241K1.79M0000
Interest Expense45M79.7M42.7M36.2M36M61.7M48.1M34.6M22.2M19.19M14.39M12.71M14.69M16.89M15.79M14.71M22.69M20.18M7.22M0000
Other Income/Expense-102.8M-134.3M-8.7M-5.4M-27.8M-105.5M-41.8M-35.5M-22.2M-19.2M-16.11M-12.65M-39.01M-15.74M-15.68M-14.58M-22.53M-12.98M89.34M53.84M34.65M21.5M332K
Pretax Income404.4M339.5M300.2M214.6M9.8M20.5M9.7M14.5M5.2M-26.6M-26.82M-61.39M-47.88M-44.87M-51.66M-57.04M-61.16M-72.34M00000
Pretax Margin %13.94%12.54%14.49%12.65%0.75%1.87%1.07%1.96%0.92%-5.74%-7.31%-23.26%-16.58%-18.16%-24.44%-37.47%-63.07%-109.56%-----
Income Tax57.7M92.4M-118.1M8.3M5.2M3.7M2.9M2.9M1.9M200K392K212K60K100K212K-11.21M000000-332K
Effective Tax Rate %14.27%27.22%-39.34%3.87%53.06%18.05%29.9%20%36.54%-0.75%-1.46%-0.35%-0.13%-0.22%-0.41%19.66%0%0%-----
Net Income302.8M247.1M418.3M206.3M4.6M16.8M6.8M11.6M3.29M-26.83M-28.88M-73.52M-51.5M-44.97M-51.87M-57.17M-61.16M-79.54M-92.79M-53.54M-35.95M-21.64M-13.82M
Net Margin %10.44%9.12%20.19%12.16%0.35%1.53%0.75%1.57%0.58%-5.79%-7.87%-27.86%-17.84%-18.2%-24.54%-37.55%-63.07%-120.46%-257.33%-400.38%-981.44%-43272%-
Net Income Growth %-24.71%-40.93%102.76%4384.78%-72.62%147.06%-41.38%252.37%112.27%7.09%60.72%-42.76%-14.51%13.29%9.28%6.52%23.11%14.28%-73.31%-48.93%-66.16%-56.54%-
Net Income (Continuing)302.8M247.1M418.3M206.3M4.6M16.8M6.8M11.6M3.3M-26.8M-27.21M-61.6M-47.94M-44.97M-51.87M-45.83M-61.16M-72.34M-94.77M-53.54M-35.95M-21.64M-13.82M
Discontinued Operations00000000000000000000000
Minority Interest00000000000000000000000
EPS (Diluted)4.313.485.782.940.070.250.100.190.05-0.46-0.50-1.29-0.93-0.83-1.08-1.22-1.54-2.68-3.36-3.21-39.19-70.95-47.64
EPS Growth %-22.66%-39.79%96.6%4368.09%-73.68%150%-47.37%251.85%111.74%8%61.24%-38.71%-12.05%23.15%11.48%20.78%42.54%20.24%-4.67%91.81%44.76%-48.93%-
EPS (Basic)-3.515.972.960.070.250.110.190.06-0.46-0.51-1.29-0.93-0.83-1.08-1.22-1.54-2.68-3.36-3.21-99.10-70.95-47.64
Diluted Shares Outstanding70.2M71.89M73.89M73.63M69.91M68.58M65.95M62.3M61.01M58M57.25M56.79M55.63M54.01M47.92M46.69M39.61M29.73M27.61M16.69M917.28K304.96K290.14K
Basic Shares Outstanding69.99M70.35M70.08M69.75M69.38M67.7M64.73M60.59M58.86M58M56.69M56.79M55.63M54.01M47.92M46.69M39.61M29.73M27.61M16.69M917.28K304.96K290.14K
Dividend Payout Ratio-----------------------

Key Metrics

Growth RegimeAccelerating
ProfitabilityModerate
Balance SheetHealthy
Cash FlowStable
Top Statement Risk

Competitive pricing and margin pressure

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Sustained Revenue Growth Momentum

According to recent quarterly filings, Insulet has demonstrated robust top-line expansion, with revenue growth accelerating to 33.9% in 2026Q1 from 23.3% in 2024Q1, largely driven by the successful market penetration of the Omnipod 5 platform and expanded access within the pharmacy channel.

The consistent double-digit growth suggests that the company is successfully capturing new patient starts despite a maturing insulin pump market. Investors should monitor whether this trajectory remains sustainable as the company attempts to penetrate the broader Type 2 diabetes population, which may require different marketing and reimbursement strategies.

Structural Gross Margin Resilience

As reported in financial statements, Insulet maintains a strong gross margin profile, consistently hovering near 70% to 72% over the last ten quarters, which underscores the significant pricing power inherent in its proprietary tubeless architecture and the efficiency of its automated manufacturing facilities.

This margin stability appears to be a direct result of the pharmacy channel shift, which typically commands higher net pricing than traditional DME models. However, any future volatility in manufacturing costs or shifts in product mix toward lower-margin segments could challenge this structural advantage.

Operating Leverage Remains Under Pressure

Based on reported figures, operating income has not scaled linearly with gross profit, as SG&A expenses have risen significantly to support global expansion, resulting in operating margins that fluctuated between 11.2% and 20.9% over the observed ten-quarter period, indicating limited near-term operating leverage.

The persistent investment in sales and marketing infrastructure suggests that management is prioritizing market share acquisition over immediate margin expansion. Analysts should investigate whether these elevated overhead costs are temporary growth-related outlays or a permanent feature of the company's competitive strategy.

Earnings Volatility Masks Operational Performance

Analysis of the income statement reveals that net income has been subject to significant quarterly swings, with EPS ranging from $0.32 to $2.59, often influenced by non-operating items and variable stock-based compensation charges that complicate the assessment of true underlying profitability.

The inconsistency in net margins suggests that investors should focus on operating income as a more reliable proxy for core business health. The periodic spikes in stock-based compensation warrant further investigation to determine the extent to which these expenses dilute shareholder value relative to operational gains.

PODD — Frequently Asked Questions

Quick answers to the most common questions about buying PODD stock.

What was Insulet Corporation's (PODD) revenue in 2025?

For fiscal year 2025, Insulet Corporation (PODD) reported total revenue of $2.71B.

Is Insulet Corporation (PODD) profitable?

Insulet Corporation (PODD) is profitable, generating $247.1M in net income for the fiscal year ending 2025 with a net profit margin of 9.1%.

What is Insulet Corporation's operating profit margin?

Insulet Corporation (PODD) reported an operating income of $473.8M, resulting in an operating profit margin of 17.5%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Insulet Corporation's gross profit and gross margin?

Insulet Corporation (PODD) generated $1.94B in gross profit for the year, representing a gross profit margin of 71.6%. This demonstrates the company's core pricing power and production efficiency.